Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896493 · ClinicalTrials.gov registry record · Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00896493: Completed Phase 2 study, sponsored by Stanford University.
NCT00896493 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896493, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary syndrome (MF/SS).
Interventions
- DRUG cyclosporine
- DRUG anti-thymocyte globulin
- RADIATION Lymphoid radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-05 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896493
The ClinicalTrials.gov registry entry for NCT00896493 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cyclosporine is the first listed.
NCT00896493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00896493 about?
NCT00896493 is a clinical study titled "Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma". Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic hemat...
What is the current status of trial NCT00896493?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2009-05. Estimated completion is 2022-12.
What interventions are being tested in trial NCT00896493?
The interventions under investigation include: cyclosporine (DRUG), anti-thymocyte globulin (DRUG), Lymphoid radiation (RADIATION).
Who is sponsoring clinical trial NCT00896493?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.